Dako expands companion diagnostics collaboration with Amgen

Will pool their knowledge of drug diagnostic R&D and companion diagnostics

Denmark-based Dako, a division of Agilent Technologies since 2012 and a provider of cancer diagnostics, has signed a new Master Collaboration Agreement with US biotechnology company Amgen.

The financial details of the agreement were not disclosed.

The companies said the expanded partnership would allow them to share their expertise in drug-diagnostic research and development and in companion diagnostic products.

They added that the collaboration is important for personalised medicine, where targeted treatments and companion diagnostics can help identify patients for whom a particular treatment may work, leading to improved patient care and more manageable healthcare costs.

Companies